Home Clinical Topics Cardio-Pulmonary FDA approves Corifact for congenital Factor XIII deficiency

FDA approves Corifact for congenital Factor XIII deficiency

The U.S. Food and Drug Administration has approved Corifact, the first product for preventing bleeding in people with congenital Factor XIII deficiency. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm243856.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here